Tested Applications
| Positive WB detected in | Calyculin A treated HeLa cells |
The antibody also detects the phosphorylated at Thr1041 of the LATS2.
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
28998-1-AP targets Phospho-LATS1 (Thr1079) in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | LATS, large tumor suppressor, homolog 1 (Drosophila) |
| Calculated Molecular Weight | 15 kDa, 127 kDa |
| Observed Molecular Weight | 140-150 kDa |
| GenBank Accession Number | BC015665 |
| Gene Symbol | LATS1 |
| Gene ID (NCBI) | 9113 |
| RRID | AB_2923586 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q6PJG3 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
The large tumour suppressor 1 (LATS1) acting as a tumour suppressor is a serine/threonine kinase of the AGC kinase family and is found to be down-regulated in various types of human cancers. Recently, LATS1 has been identified as a central player of the emerging tumour suppressive Hippo signaling pathway. In this pathway, the MST1/2 kinase phosphorylates activates LATS1/2 which, together with its co-factor MOB1, subsequently phosphorylates and inhibits the YAP transcriptional factor by preventing them from translocating to the nucleus. The antibody also detects the phosphorylated at Thr1041 of the LATS2. (PMID: 32460168, PMID: 30219064,PMID: 31792377)
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for Phospho-LATS1 (Thr1079) antibody 28998-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Phospho-LATS1 (Thr1079) Polyclonal antibody (Cat# 28998-1-AP) has 35 citations published in journals including Journal of Advanced Research, Advanced Science, Molecular Biomedicine, Cell Death & Disease, International Journal of Biological Sciences, Journal of Translational Medicine, Radiotherapy and Oncology, and Drug Design, Development and Therapy. Research fields span cancer biology (lung, liver, renal, ovarian, colorectal), Hippo-YAP signaling, fibrosis, mechanobiology, cardiac pathology, and environmental toxicology.
| Species | Application | Title |
|---|---|---|
J Adv Res Matrix stiffness drives squamous cell carcinoma progression via a Piezo1-mediated mechanotransduction feedback loop. | ||
Adv Sci (Weinh) The E3 Ligase RNF115 Aggravates Pathological Cardiac Hypertrophy via Ubiquitin-Mediated Degradation of SPTBN1. | ||
Mol Biomed The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation | ||
Cell Death Dis PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling | ||
Cell Mol Biol Lett KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway | ||
Int J Biol Sci S100 Calcium Binding Protein A16 Promotes Cell Proliferation by triggering LATS1 ubiquitin degradation mediated by CUL4A ligase to inhibit Hippo pathway in Glioma development |
